Navigation Links
Neurelis Announces FDA Allowance of IND Application for NRL-1, a Novel Intranasal Diazepam Formulation
Date:2/6/2012

s are uncontrolled on oral therapy and are at-risk for acute breakthrough seizures.  Studies have shown that prolonged or repetitive seizures can cause neurological damage and dramatically increase the risk of changes in neuropsychological function or even death. 

Presently, the only product approved for the treatment of acute repetitive seizures outside of the hospital setting, is a rectally administered formulation of diazepam called Diastat®.  Because of its rectal mode of administration, Diastat® has been primarily relegated to use in younger pediatric patients (usually less than 10 years of age).  The majority of patients with acute repetitive seizures; however, are currently seen in emergency rooms and treated with intravenous benzodiazepines.  Most of these patients are admitted to the hospital.  This represents a significant component of the estimated $15 billion annual economic burden on the system to treat epilepsy in the U.S.  Intranasal diazepam would provide a more convenient alternative to either rectal administration of Diastat® or the need to visit the emergency room for intravenous administration of drugs.

About Neurelis

Neurelis, Inc. is a San Diego-based specialty pharmaceutical company organized to license, develop, and commercialize product candidates for epilepsy and the broader central nervous system ("CNS") market.  Neurelis leverages expertise in the development and commercialization of CNS compounds and strong relationships with leading researchers and clinicians in these markets to advance unique product candidates to address significant unmet medical needs.

Contact: David F. Hale
858-756-2480
Email: salaimo@neurelis.com

 

 

 


'/>"/>
SOURCE Neurelis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)
2. Neurelis Announces Positive Results from Phase 1 Pharmacokinetic Study of NRL-01 (intranasal diazepam)
3. Neurelis Announces Completion of Dosing in Study of Intranasal Diazepam
4. Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection
5. Genomic Health Announces Formation of New Genetics Subsidiary
6. Aria Diagnostics Announces Name of New Non-Invasive Prenatal Assay - Harmony Prenatal Test™ - and Publication of Study on Specimen Transport
7. Amrita Hospital Information System Announces its First Hospital Meaningful Use Attestation!
8. InspireMD Announces Positive Clinical Data From Trial of MGuard™
9. Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Companys Synthetic Biologics Strategic Focus
10. Cempra, Inc. Announces Pricing of Its Initial Public Offering of Common Stock
11. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2011 Earnings Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014  Northstar Global Business Services, Inc. ... (DTC) has made their final decision and has ... Company,s stock effective December 15, 2014, and has ... depository and book entry transfer services. All deposit restrictions ... once again fully "DTC Eligible", and has resumed ...
(Date:12/17/2014)... 17, 2014 , ... a hub of information concerning the biopharmaceutical Group,s national and ... further addition to the recently launched institutional website that is ... been enriched by a new chapter in the fascinating story ... richly detailed and panoramic hub on the world of clinical ...
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... IDAHO FALLS, Idaho, Dec. 12, 2011 International Isotopes ... a conference call to give an update of the ... performance of its core business segments as well as ... depleted uranium de-conversion project.What:  , International Isotopes Inc. General ...
... of Eli Lilly and Company (NYSE: LLY ) ... December 12, 2011. Baicker, 40, is Professor of Health Economics ... Harvard School of Public Health. She is also a research ... elected member of the Institute of Medicine. As a member of ...
Cached Medicine Technology:International Isotopes Inc. Announces Conference Call to Give an Update on the Company's General Business Status 2Katherine Baicker Elected to Lilly Board of Directors 2
(Date:12/19/2014)... It’s very easy to become overwhelmed with the ... to the wayside until Christmas and the New Year are ... and that burning desire to just escape it all and ... to Telluride with a no-fuss, affordable package. Montrose Days Inn ... resort, and ensure that all accommodations are met. Plus, everyone ...
(Date:12/19/2014)... Energy Textiles is excited to ... Celliant, the world’s leading responsive textile, can now ... There are a number of benefits to wearing ... and balanced body temperature; which can lead to ... enhanced athletic performance; and overall wellness. In addition, ...
(Date:12/19/2014)... 19, 2014 SuperCloset raises the bar ... SuperCloset continues to offer indoor growers the most efficient ... the new SuperClone Rooms with the award winning ... indoor hydroponic grow room setup. , The SuperClone Room ... SuperPonic SuperCloner 50 . The SuperClone ...
(Date:12/19/2014)... 2014 An evening dress is perfect for ... closet. Discount-Dress.com, a distinguished dresses retailer, has unveiled its new ... in this great shopping platform. Customers can view ... hard work, Discount-Dress.com has been accepted and praised by customers ... easier shopping stage for clients. In order to expand its ...
(Date:12/19/2014)... warns parents that buying an older car for their teens may ... drivers killed in the United States between 2008 and 2012 were ... lacked important safety features that are available on newer cars, the ... were in cars at least six years old, 34 percent were ... cars 11 to 15 years old, and 17 percent were in ...
Breaking Medicine News(10 mins):Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Older Cars a Bad Choice for Younger Drivers 2
... The Food Allergy &,Anaphylaxis Network (FAAN) will hold ... May 31, 2008. Many families struggle with,how best to ... living with food allergies for years or are dealing ... attendees will learn tips and strategies for living better,while ...
... potent cancer gene. , The gene, known as ERG, ... including leukemia and sarcoma. American scientists showed in 2005 that ... cancers. , It was unclear, however, what function ERG ... so carcinogenic when mutated. , The team at WEHI ...
... Assisted living communities save time and money accepting ... electronic payments direct from resident bank accounts, ... today that it,has added PaySimple, the leading provider ... its customers to help simplify resident billing,and collection ...
... 27 Health Fitness,Corporation (OTC Bulletin Board: HFIT), ... management solutions, today announced that,it has completed its ... plan, the company repurchased 1.14 million shares of ... with Securities and Exchange,Commission Rule 10b-18 and other ...
... to be poorer and without insurance , , TUESDAY, May 27 ... receive treatment, even though they have access to care, according ... funding from drug maker GlaxoSmithKline, was published in the May ... . , The research involved 97 Boston-area men with the ...
... The current recommended daily allowance (RDA) of vitamin D ... research reveals that children may need and can safely ... report in The Endocrine Societys Journal of Clinical Endocrinology ... bone health of children worldwide and may have other ...
Cached Medicine News:Health News:FAAN Brings 'Food Allergies: Living and Learning' to Annual Food Allergy Conference in New York 2Health News:FAAN Brings 'Food Allergies: Living and Learning' to Annual Food Allergy Conference in New York 3Health News:Vigilan Offers PaySimple to Simplify Resident Billing and Collection 2Health News:Health Fitness Completes Share Repurchase Plan 2Health News:Men With Low Testosterone Not Receiving Treatment 2Health News:Current vitamin D recommendations fraction of safe, perhaps essential levels for children 2
... path that allows users to take full ... potential to combine two units offers fully ... stimulating coil. The ability to change pulse ... level of each Magstim 200 allows for ...
... is a surgical approach to glaucoma management ... application. The ciliary body (which produces aqueous ... the anterior or posterior segment, through the ... are easily and accurately identified utilizing endoscopy. ...
... surgical approach to glaucoma management that employs ... ciliary body (which produces aqueous humour) is ... or posterior segment, through the endoscope in ... and accurately identified utilizing endoscopy. This allows ...
... of German Craftsmanship have produced ... the world. Ocutek® now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
Medicine Products: